Fig. 1From: Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort studyThe CMR parameters in patients with ATTR-CM and healthy controlBack to article page